|
Accrued expenses consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
December 31,
2022 |
|
|
December 31,
2021 |
|
|
|
|
|
|
|
|
Accrued pre-clinical and clinical costs |
|
$ |
2,137,317 |
|
|
$ |
5,435,464 |
|
Accrued product development costs |
|
|
247,500 |
|
|
|
203,676 |
|
Accrued compensation |
|
|
2,224,951 |
|
|
|
2,715,368 |
|
Accrued administrative costs |
|
|
473,376 |
|
|
|
1,213,699 |
|
Accrued interest |
|
|
916,108 |
|
|
|
525,105 |
|
Total |
|
$ |
5,999,252 |
|
|
$ |
10,093,312 |
|
|